Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tragara Pharmaceuticals Inc.

Latest From Tragara Pharmaceuticals Inc.

Jinghua Aims To Transform Through Kadmon Biologics Alliance

China-listed Jinghua Pharmaceutical has tapped into developing biologic drug through investment and licensing agreement with US-based Kadmon, shifting from a traditional Chinese medicine maker to mAbs developer. The company has seen increasing competition and revenue drops in Chinese traditional medicine industry.

BioPharmaceutical China

Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations

DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.

BioPharmaceutical Deals

Polynoma's poly senior management appointments

Oncology-focused US biotech Polynoma, part of the Hong Kong company CK Life Sciences, has expanded its senior management team with three appointments: Dr Sara Zaknoen joins as chief medical officer, Andrew Buckland as chief financial officer and Patrick Mallon as chief operating officer. Dr Zaknoen joins from Tragara Pharmaceuticals where she was CMO; Mr Buckland most recently served as CFO of PURE Bioscience; and Mr Mallon was previously CEO at Genpathway having previously served at Roche, Gen-Probe and Agouron.

Hong Kong

Novogen oncology spin-out MEI acquires pracinostat as S*BIO divests more assets

The publicly-traded Novogen oncology spin-out MEI Pharma has acquired pracinostat (SB939), an oral histone deacetylase (HDAC) inhibitor, for just $500,000 in MEI stock upfront, from Singapore-based S*BIO, as the private company's investors divest the last of its cancer drug assets.

Cancer Respiratory
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tragara Pharmaceuticals Inc.
  • Senior Management
  • Thomas M Estok, Pres. & CEO
    Tracy Lawhon, VP, Reg. Affairs & Dev. Operations
  • Contact Info
  • Tragara Pharmaceuticals Inc.
    Phone: (858) 350-6900
    10955 Vista Sorrento Pkwy.
    Ste. 120
    San Diego, CA 92130